Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome

In a phase 3 randomized trial, 199 patients with type 1 hepatorenal syndrome were assigned to receive the vasoconstrictor terlipressin plus albumin and 101 to receive placebo plus albumin. Renal function was better with terlipressin than with placebo; however, mortality was not lower, and terlipress...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-03, Vol.384 (9), p.818-828
Hauptverfasser:	Wong, Florence, Pappas, S. Chris, Curry, Michael P, Reddy, K. Rajender, Rubin, Raymond A, Porayko, Michael K, Gonzalez, Stevan A, Mumtaz, Khalid, Lim, Nicholas, Simonetto, Douglas A, Sharma, Pratima, Sanyal, Arun J, Mayo, Marlyn J, Frederick, R. Todd, Escalante, Shannon, Jamil, Khurram
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Albumin Albumins - therapeutic use Ascites Cardiovascular disease Cirrhosis Clinical practice guidelines Combined Modality Therapy Consent Creatinine Diarrhea Double-Blind Method Female Hemodynamics Hepatorenal Syndrome - drug therapy Hepatorenal Syndrome - etiology Hepatorenal Syndrome - mortality Humans Inflammation Infusions, Intravenous Liver Liver cirrhosis Liver Cirrhosis - complications Liver Transplantation Male Middle Aged Mortality Nausea Patients Placebos Renal function Renal Replacement Therapy Respiratory failure Respiratory Insufficiency - chemically induced Success Systemic inflammatory response syndrome Terlipressin - adverse effects Terlipressin - therapeutic use Treatment Outcome Vasoconstrictor Agents - adverse effects Vasoconstrictor Agents - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a phase 3 randomized trial, 199 patients with type 1 hepatorenal syndrome were assigned to receive the vasoconstrictor terlipressin plus albumin and 101 to receive placebo plus albumin. Renal function was better with terlipressin than with placebo; however, mortality was not lower, and terlipressin was associated with adverse events, including respiratory failure.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2008290